Location: Exotic & Emerging Avian Viral Diseases Research
Project Number: 6040-32000-072-008-T
Project Type: Trust Fund Cooperative Agreement
Start Date: Dec 1, 2014
End Date: Dec 1, 2019
Objective:
To develop a bivalent vaccine against Newcastle disease virus (NDV) and infectious laryngotracheitis virus (ILVT).
Approach:
The approach will be to first create an infectious clone of ILTV and rescue a recombinant ILTV (rILTV). Next the fusion (F) gene of NDV will be inserted into the middle of one of the ILTV genes that is a virulence factor. This insertion will decrease the virulence of the ILTV, attenuating the virus so that clinical respiratory disease is less likely. In addition, this insertion will give the ability to differentiate infected from vaccinated animals (DIVA). Lastly, the expression of the F protein will provide the antigen for the induction of NDV neutralizing antibodies. Safety and efficacy studies will take place in SPF and commercial birds to document safety and protection levels against an ILTV and virulent NDV challenge.
